Pfizer Antes Up $110 Million To Buy In To Cancer Cell Therapy Race - Presented by: The Aol. On Network

Fresh from its failed (or at least paused) attempt to acquire rival AstraZeneca, Pfizer has made a big bet on one of the hottest new technologies in cancer: genetically engineered white blood cells that hunt down tumors and destroy them. Pfizer announced this morning that it will pay Cellectis, a French biotechnology company, an $80 million upfront payment for the company’s T-cell technology, in addition to purchasing about $30 million in stock.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 18.16 0.28 ▲ 1.57%
TWTR $ 31.24 5.30 ▼ 14.50%
F $ 15.21 0.53 ▲ 3.61%
CFG $ 26 0.17 ▼ 0.65%
FB $ 96.99 1.70 ▲ 1.78%
PFE $ 35.76 0.41 ▲ 1.16%
MU $ 19.87 0.12 ▲ 0.61%
MSFT $ 46.29 0.95 ▲ 2.10%

As of 7/29/2015, 04:15 PM